| Description | Tetrahydrobiopterin (BH4) is a cofactor for aromatic amino acid hydroxylases and an essential cofactor for nitric oxide synthase (NOS), which is used in the study of endothelial dysfunction such as hypertension, hypercholesterolemia, and diabetes. |
| In vitro | Microglia cultures under hyperoxic conditions were supplemented with or without Tetrahydrobiopterin (100 μM). Exposure of microglia to hyperoxia-induced oxidative stress for 24 h showed a significant increase in TSP-1 mRNA expression and protein compared with normoxia (21% O2). Tetrahydrobiopterin supplementation significantly prevents hyperoxia-induced microglial activation and prevents microvascular damage in choroidal explants by reducing Iba-1 and TSP-1 expression.[1] |
| In vivo | To assess the levels of tetrahydrobiopterin in the retina, three to five retinal pools were collected from WT and HPH-1 mice at postnatal ages 7, 14, and 22 years and evaluated by LC-MS/MS. LC-MS/MS analysis confirmed that the concentration level of tetrahydrobiopterin in the retinal tissue of HPH-1 mice was significantly reduced by approximately 90% compared with WT groups P7, P14, and P22, respectively.[1] |
| Synonyms | Sapropterin, BH4, (Rac)-Sapropterin |
| molecular weight | 241.25 |
| Molecular formula | C9H15N5O3 |
| CAS | 17528-72-2 |
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 40 mg/mL (165.80 mM), Sonication is recommended. |
| References | 1. Rivera JC, et al. Tetrahydrobiopterin (BH4) deficiency is associated with augmented inflammation and microvascular degeneration in the retina. J Neuroinflammation. 2017 Sep 6;14(1):181. |